期刊文献+

依巴斯汀联合布地奈德治疗变应性鼻炎(AR)的疗效及对炎性因子、T淋巴细胞亚群的影响 被引量:1

Ebastine combined with budesonide in the treatment of allergic rhinitis(AR)and its effect on inflammatory factors and T lymphocyte subsets
下载PDF
导出
摘要 目的探究与分析依巴斯汀联合布地奈德治疗变应性鼻炎(AR)的疗效及对炎性因子及T淋巴细胞亚群的影响。方法选取菏泽市中医医院自2018年5月~2020年5月收治的AR患者120例,采取随机数表法分为单药组与联合组,每组60例,单药组仅给予布地奈德喷剂治疗,联合组在单药组基础上加用依巴斯汀治疗,对比两组临床疗效、炎性因子、T淋巴细胞亚群水平。结果联合组临床总有效率高于单药组,差异有统计学意义(P<0.05)。联合组治疗后与单药组治疗后相比血清IL-4、IL-6及IL-10水平均降低,差异有统计学意义(P<0.05)。联合组治疗后与单药组治疗后相比CD^(+)_(3)较高、CD^(+)_(4)较高、CD^(+)_(8)较低、CD^(+)_(4)/CD^(+)_(8)较高,差异有统计学意义(P<0.05)。结论依巴斯汀联合布地奈德治疗AR可有效改善患者的临床症状及体征,减轻炎性反应,调节细胞免疫功能。 Objective To explore and analyze the efficacy of ebastine combined with budesonide in the treatment of allergic rhinitis(AR),and its influence on inflammatory factors and T lymphocyte subsets.Methods A total of 120 AR patients admitted to our hospital from May 2018 to May 2020 were selected and divided into single-drug group and combination group by random number table,60 cases in each group,and only budesonide in the single-drug group.For spray treatment,the combination group was treated with ebastine on the basis of the single-drug group,and the clinical efficacy,inflammatory factors,and T lymphocyte subgroup levels were compared between the two groups.Results The total clinical effective rate of the combined group was higher than that of the single-drug group,with statistical significance(P<0.05).Serum levels of IL-4,IL-6 and IL-10 in the combination group were significantly lower than those in the single-agent group after treatment,with statistical significance(P<0.05).Compared with the single-agent group after treatment,the combination group had higher CD^(+)_(3),higher CD^(+)_(4),lower CD^(+)_(8),higher CD^(+)_(4)/CD^(+)_(8),with statistical significance(P<0.05).Conclusion Ebastine combined with budesonide in the treatment of AR can effectively improve the clinical symptoms and signs of patients,reduce inflammatory reactions,and regulate cellular immune function.There are no obvious adverse reactions during the treatment period and the safety is high.
作者 王新龙 WANG Xin-long(Department of Otorhinolaryngology,Heze Hospital of Traditional Chinese Medicine,Shandong Heze,274000,China)
出处 《中华养生保健》 2021年第13期3-5,共3页 CHINESE HEALTH CARE
关键词 依巴斯汀 布地奈德 AR 疗效 炎性因子 T淋巴细胞亚群 Ebastine Budesonide AR Efficacy Inflammatory factors T lymphocyte subsets
  • 相关文献

参考文献17

二级参考文献145

共引文献386

同被引文献15

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部